Interim FRONTIER4 results showed low bleed rates across dosing schedules in 426 hemophilia A participants, while separate explorer10 data found concizumab cut annualized bleeding rates 82% versus prior on-demand treatment in children with inhibitors.
verifying reliability
No specialized terms available for this topic.